Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab monotherapy versus epcoritamab plus lenalidomide as first-line treatment for anthracycline-ineligible diffuse large B-cell lymphoma
2021-005744-29Phase 2Active
- Sponsor
- Genmab
- Start
- Aug 2022
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma comparing Epcoritamab monotherapy with Epcoritamab plus lenalidomide (2 arms). Primary endpoint: Complete response rate. Started Aug 2022; status: active.
02
Drugs
epcoritamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2021-005744-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005744-29.